Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064848 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2METAP2METAP1NPY5RAKT2 | |
| Triphosphate SCHEMBL13857851 | 0.82 | METAP2 (0.39) | SMN1; SMN2METAP2METAP1NPY5RENPP1 | |
| SCHEMBL7072867 | 0.79 | NUDT1 (0.49) | SMN1; SMN2METAP2METAP1NPY5RENPP1 | |
| SCHEMBL1445584 | 0.79 | NUDT1 (0.49) | SMN1; SMN2METAP2METAP1NPY5RENPP1 | |
| SCHEMBL9121473 | 0.76 | METAP2 (0.45) | SMN1; SMN2METAP2METAP1NPY5RENPP1 | |
| SCHEMBL3894 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL3801779 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1HTT | |
| SCHEMBL5632 | 0.75 | NUDT1 (0.50) | METAP2METAP1NPY5RALDH1A1EGFR | |
| SCHEMBL277596 | 0.75 | METAP2 (0.51) | METAP2METAP1NPY5RENPP1GRIN2B | |
| SCHEMBL30388675 | 0.75 | NUDT1 (0.50) | METAP2METAP1NPY5RALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283063-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4514954-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-05 | — | — | EP | claimed |
| EP-4514953-A1 | NOVEL CRISPR-CAS12F SYSTEMS AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-05 | — | — | EP | claimed |
| CN-119421948-A | Novel CRISPR-Cas12f system and application thereof | 辉大(上海)生物科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119331309-A | Methyl purine ferulic acid aromatized water magnesite composite material and preparation method and application thereof | 江西广源化工有限责任公司 | 2025-01-21 | — | — | CN | claimed |
| CN-118749029-A | Novel CRISPR-Cas12i system and application thereof | 辉大(上海)生物科技有限公司 | 2024-10-08 | — | — | CN | claimed |
| WO-2024094084-A1 | ISCB POLYPEPTIDES AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2024-05-10 | — | — | WO | claimed |
| CN-117820252-A | Preparation and detection methods of nitroreductase hemicyanine dye fluorescent probes and visual application of nitroreductase hemicyanine dye fluorescent probes in clinical bacterial identification | 华北理工大学 | 2024-04-05 | — | — | CN | claimed |
| CN-114410836-B | Kit and method for detecting human parvovirus B19 by integrating sample treatment, nucleic acid extraction and multiplex isothermal amplification | 上海交通大学医学院附属仁济医院 | 2024-03-01 | — | — | CN | claimed |
| CN-117460822-A | Novel CRISPR-Cas12i system and application thereof | 辉大基因治疗(新加坡)私人有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-1499628-A4 | RNA INTERFERENCE MEDIATED INHIBITION OF STEAROYL-COA DESATURASE (SCD) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1515985-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF MUTANT P53 | El-Gewely, Mohammed Raafat (NO) | 2005-03-23 | — | — | EP | claimed |
| EP-1499628-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF STEAROYL-COA DESATURASE (SCD) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| EP-1499631-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003072600-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF TARGET PROTEINS AND PEPTIDES THAT RESTORE THE FUNCTION OF MUTANT P53 | GARDNER, REBECCA, KATHERINE (GB) | 2003-09-04 | — | — | WO | claimed |
| WO-2003070885-A2 | SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| WO-2003070197-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030134819-A1 | Recombinant bacterial cells for delivery of PNP to tumor cells | SOUTHERN RESEARCH INSTITUTE | 2003-07-17 | — | — | US | claimed |
| CN-1172417-A | Feed for fishes and shellfishes | PROD DEV RES INST (JP) | 1998-02-04 | — | — | CN | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283063-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | RBM12, PRR12, HM13 | SMN1; SMN2 2847/4885METAP2 1097/4885METAP1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.